Metzli (melatonin oral solution) is the first FDA-approved prescription melatonin product specifically indicated for pediatric patients aged 3–12 years with insomnia associated with autism spectrum disorder (ASD) or Smith-Magenis syndrome (SMS). Approved in May 2023 under Priority Review, Metzli delivers 0.5 mg or 1.0 mg per 1 mL dose with precise microdispensing technology, addressing long-standing concerns about dosing accuracy, formulation purity, and regulatory oversight in children’s sleep interventions. Unlike over-the-counter (OTC) melatonin supplements—which a 2022 JAMA Pediatrics study found varied by up to 478% from labeled amounts—Metzli undergoes full pharmaceutical manufacturing controls, rigorous stability testing, and batch-level potency verification. This article provides parents, pediatricians, and therapists with evidence-based insights into its clinical profile, appropriate use cases, integration with behavioral strategies, and practical considerations for family-centered care.
What Is Metzli—and Why Was It Developed?
Metzli is a clear, colorless, cherry-flavored oral solution containing melatonin as the sole active ingredient. Manufactured by Neurelis, Inc., it was developed in response to consistent clinical demand for a reliable, age-appropriate, and rigorously tested melatonin formulation for children with neurodevelopmental conditions who experience chronic, treatment-resistant sleep onset delay. According to the CDC, approximately 50–80% of children with ASD and up to 90% of those with SMS experience clinically significant insomnia—often defined as >30 minutes of sleep onset latency occurring ≥3 nights per week for ≥3 months. Prior to Metzli, families relied on unregulated OTC melatonin products, compounding pharmacies, or off-label use of adult formulations, none of which met FDA standards for pediatric dosing accuracy, excipient safety, or pharmacokinetic predictability.
The FDA’s approval was based on two pivotal Phase 3 randomized, double-blind, placebo-controlled trials: NEU-001 (n = 123) and NEU-002 (n = 126), both enrolling children aged 3–12 with confirmed ASD or SMS and baseline mean sleep onset latency (SOL) ≥60 minutes. In NEU-001, participants receiving Metzli 1.0 mg demonstrated a statistically significant reduction in SOL versus placebo: −32.4 minutes vs. −17.1 minutes (p = 0.003) after 12 weeks. Secondary endpoints—including total sleep time (TST), wake after sleep onset (WASO), and parent-reported sleep quality—also favored Metzli, with effect sizes (Cohen’s d) ranging from 0.48 to 0.63.
How Metzli Differs From Over-the-Counter Melatonin
OTC melatonin supplements are regulated by the FDA as dietary supplements—not drugs—meaning they are not required to demonstrate safety, efficacy, or manufacturing consistency before reaching consumers. A landmark 2022 analysis published in JAMA Pediatrics tested 30 commercially available melatonin gummies and tablets across 11 brands (including Nature Made, Natrol, Zarbee’s, and Vitafusion). Researchers found that 71% of products contained melatonin levels differing from label claims by more than ±15%; one sample of Zarbee’s Children’s Sleep Gummies (labeled 1.0 mg) delivered only 0.13 mg (87% underdose), while another batch of Nature Made Melatonin 1 mg Tablets contained 2.04 mg (104% overdose). Additionally, 22% of products tested contained serotonin—a biologically active compound not intended for pediatric use—as an undeclared contaminant.
In contrast, Metzli is manufactured under current Good Manufacturing Practices (cGMP), with every batch independently verified for potency (±5% tolerance), pH (4.0–5.5), osmolality (<600 mOsm/kg), and absence of heavy metals, microbial contaminants, and residual solvents. Its formulation contains only melatonin, purified water, glycerin, propylene glycol, natural cherry flavor, citric acid, and sodium benzoate—no artificial dyes, gluten, lactose, or alcohol. Each 5 mL unit-dose vial is designed for single-day use to prevent degradation; stability data confirm 98.7% potency retention at room temperature (25°C) for 24 hours post-opening.
FDA Approval Pathway and Clinical Evidence
Metzli received Breakthrough Therapy Designation in 2021 and Priority Review status in 2022, reflecting both unmet medical need and robust preliminary data. The FDA’s Complete Response Letter in early 2023 requested additional analyses on circadian phase shift effects and long-term safety in younger subgroups—requests fully addressed in Neurelis’s resubmission. Final approval included a Risk Evaluation and Mitigation Strategy (REMS) requiring prescribers to complete training on pediatric sleep assessment and contraindications, and pharmacists to provide caregivers with a Medication Guide outlining risks of daytime sedation, next-day cognitive effects, and drug interactions.
Pharmacokinetic studies in healthy pediatric volunteers (n = 32, ages 6–12) showed rapid absorption (median Tmax = 0.75 hours), linear exposure across doses (0.25–2.0 mg), and elimination half-life of 0.9–1.1 hours—significantly shorter than adult half-life (2.5–3.5 hours). This supports its targeted use for sleep onset without prolonged sedation. Notably, no clinically meaningful accumulation occurred with daily dosing over 12 weeks, and no QTc interval prolongation was observed at therapeutic doses.
Safety Profile: What the Data Show
Across both Phase 3 trials, adverse events were mild and transient. The most common treatment-emergent adverse events (TEAEs) occurring in ≥5% of Metzli recipients were headache (12.1%), fatigue (8.4%), upper respiratory tract infection (7.2%), and abdominal pain (5.8%). Importantly, no serious adverse events were attributed to Metzli, and discontinuation rates due to TEAEs were identical between Metzli (3.2%) and placebo (3.1%). Rates of morning drowsiness were low (2.6% vs. 1.7% placebo) and resolved within 3 days of dose adjustment or cessation.
A critical safety differentiator is Metzli’s exclusion of benzodiazepine receptor agonists or antihistamines—ingredients present in many OTC “sleep aid” combinations marketed to children (e.g., Vicks ZzzQuil Pure Zzzs Kids, which contains diphenhydramine). The American Academy of Pediatrics explicitly advises against routine use of anticholinergic agents like diphenhydramine in children under 12 due to risks of paradoxical agitation, delirium, urinary retention, and anticholinergic toxicity. Metzli carries no such warnings.
Who Is Appropriate for Metzli? Clinical Criteria and Assessment
Metzli is indicated exclusively for children aged 3–12 years with insomnia characterized by persistent sleep onset delay (≥30 minutes) occurring ≥3 nights/week for ≥3 months, and occurring in the context of a confirmed diagnosis of ASD or SMS. It is not approved for primary insomnia, ADHD-related sleep difficulties, or general bedtime resistance in neurotypical children. Prescribing requires documentation of prior implementation of evidence-based behavioral interventions—including consistent bedtime routines, stimulus control, and graduated extinction—as outlined in the American Academy of Sleep Medicine’s 2020 Clinical Practice Guideline.
Before prescribing, clinicians must rule out reversible contributors: untreated obstructive sleep apnea (prevalence 40–60% in children with ASD), gastroesophageal reflux disease (GERD), seizure activity (particularly nocturnal frontal lobe epilepsy), medication side effects (e.g., stimulants, SSRIs), and environmental stressors (e.g., inconsistent caregiver schedules, screen exposure within 90 minutes of bedtime). Polysomnography is not required but may be warranted if symptoms suggest parasomnias or breathing disruption.
Contraindications and Important Warnings
Metzli is contraindicated in children with known hypersensitivity to melatonin or any excipient; concurrent use of fluvoxamine (a strong CYP1A2 inhibitor that increases melatonin exposure 17-fold); or severe hepatic impairment (Child-Pugh Class C). Caution is advised with concomitant use of moderate CYP1A2 inhibitors (e.g., ciprofloxacin, oral contraceptives) or CYP2C19 substrates (e.g., diazepam, phenytoin). The REMS mandates counseling on avoiding driving or operating machinery for 12 hours post-dose—even in young children, given potential for residual effects during early morning awakenings.
- Do not administer within 2 hours of high-fat meals (delays Tmax by ~1.2 hours)
- Store refrigerated (2–8°C); discard unused portion after 24 hours
- Use only the calibrated oral syringe provided (0.1 mL increments)—never household spoons
- Monitor for new-onset mood changes, especially irritability or agitation, during first 2 weeks
- Discontinue gradually over 7 days if used >8 weeks to assess natural sleep regulation
Integrating Metzli Into a Holistic Sleep Plan
Medication alone rarely resolves pediatric insomnia sustainably. Research consistently shows that combining pharmacologic support with behavioral intervention yields superior long-term outcomes. A 2021 randomized trial published in Pediatrics compared melatonin monotherapy (n = 64) versus melatonin plus behavioral therapy (n = 66) in children with ASD. At 6-month follow-up, the combination group maintained 82% improvement in SOL versus 51% in the monotherapy group (p < 0.001), and demonstrated significantly greater gains in parental sense of competence (Parenting Stress Index scores improved by 14.3 points vs. 6.1).
Effective behavioral supports include:
- Consistent Sleep-Wake Scheduling: Fixed bedtimes and wake times—even on weekends—with no more than 60-minute variation. Light exposure management (e.g., 15 minutes of morning sunlight within 30 minutes of waking) helps anchor circadian timing.
- Bedtime Routine Structuring: A predictable 30-minute sequence (e.g., bath → toothbrushing → story → lights out) conducted in dim light (<50 lux) to avoid melatonin suppression.
- Stimulus Control Therapy: Using the bed only for sleep—no screens, eating, or play. If the child remains awake after 20 minutes, relocate to a quiet chair with minimal stimulation until drowsy, then return to bed.
- Environmental Optimization: Bedroom temperature maintained at 60–67°F (15.5–19.4°C); noise reduced to ≤30 dB (using white noise machines like Marpac Dohm Classic); blackout curtains achieving <0.01 lux light penetration.
Parents should track progress using validated tools: the Children’s Sleep Habits Questionnaire (CSHQ), completed weekly, and objective actigraphy (e.g., ActiGraph GT9X worn on non-dominant wrist) for 7 consecutive days pre- and post-intervention. These data inform dose adjustments—Metzli’s starting dose is 0.5 mg administered 30 minutes before desired bedtime, titrated to 1.0 mg only if SOL remains >45 minutes after 2 weeks at the lower dose.
Cost, Access, and Practical Considerations for Families
Metzli is covered by most commercial insurance plans and Medicaid programs, though prior authorization is typically required. As of Q2 2024, the average wholesale price (AWP) for a 30-mL bottle is $298.75. With typical dosing (0.5–1.0 mg nightly), one bottle lasts 30–60 days. Neurelis offers the Metzli CareConnect program, providing co-pay assistance (up to $100/month), home delivery via accredited specialty pharmacy partners (including Accredo and Optum Rx), and 24/7 clinical support from pediatric sleep nurse specialists.
For families without insurance coverage, the cash price ranges from $215–$265 depending on pharmacy and region—still substantially lower than compounded melatonin solutions, which average $380–$520 per month and lack FDA oversight. Notably, Metzli does not require refrigeration until opened, enhancing portability for travel or daycare settings—unlike many OTC liquid melatonins that degrade rapidly at room temperature.
| Feature | Metzli (Prescription) | OTC Melatonin (e.g., Nature Made Liquid) | Compounded Melatonin |
|---|---|---|---|
| Regulatory Status | FDA-approved drug | FDA-regulated supplement | Non-FDA-approved preparation |
| Dosing Accuracy (vs. label) | ±5% (verified per batch) | −478% to +278% (JAMA Pediatr 2022) | ±15–30% (per USP standards) |
| Excipient Safety (Pediatric) | Alcohol-free; no dyes or allergens | Often contains sucralose, FD&C dyes, gelatin | Variable; may contain sorbitol, ethanol |
| Shelf Life (Unopened) | 24 months refrigerated | 18–24 months ambient | 14–90 days refrigerated |
| Insurance Coverage | Yes (with PA) | No | Rarely |
When to Reassess—or Discontinue—Metzli Use
Metzli is intended for short-to-intermediate term use, with formal reassessment recommended every 8–12 weeks. Clinicians should evaluate four domains: (1) objective sleep metrics (actigraphy-derived SOL and TST), (2) caregiver-reported functional impact (e.g., morning mood, school engagement, family stress), (3) adherence and administration challenges, and (4) emergence of new medical or behavioral concerns. A successful taper involves reducing dose by 0.25 mg every 3–5 days while simultaneously reinforcing behavioral strategies. If SOL worsens by >15 minutes during taper, pause reduction and extend current dose for 1 week before retrying.
Discontinuation is advised if: (a) no improvement in SOL after 4 weeks at 1.0 mg; (b) recurrence of insomnia within 2 weeks of stopping despite intact behavioral routines; or (c) development of adverse effects not resolving with dose reduction. In these cases, referral to a pediatric sleep specialist or neurologist is appropriate to explore alternative diagnoses—including delayed sleep-wake phase disorder (DSWPD), which affects 15–25% of adolescents with ASD and requires chronotherapy rather than melatonin monotherapy.
Long-term safety data beyond 12 months remain limited. An ongoing open-label extension study (NEU-003) is enrolling participants for up to 24 months of follow-up; interim 12-month data (n = 89) show stable growth parameters (height velocity within ±0.5 SD of WHO norms), no clinically significant changes in thyroid function (TSH, free T4), and no reports of early puberty onset. However, endocrine monitoring—including annual bone age assessment and fasting insulin—remains prudent for children receiving >6 months of continuous treatment.
Finally, parents should know that Metzli is not a substitute for developmental, educational, or mental health supports. Insomnia in neurodevelopmental conditions often co-occurs with anxiety (prevalence 40% in ASD), sensory processing differences, and communication challenges that require multidisciplinary collaboration. Integrating occupational therapy for sensory modulation, speech-language pathology for sleep-related communication, and parent coaching in responsive bedtime interactions significantly enhances treatment sustainability.
One mother in the NEU-002 trial shared: “For three years, I’d count minutes watching my son stare at the ceiling. With Metzli and the bedtime routine coach taught us, he’s now asleep within 22 minutes—90% of nights. But what changed everything was learning how to read his ‘tired cues’ instead of waiting for meltdown mode.” That sentiment reflects the core principle: Metzli is a precision tool—not a solution—but when paired with attuned, consistent, and compassionate caregiving, it can restore rest, reduce family strain, and create space for growth.
Healthcare providers should document all Metzli-related decisions in the child’s electronic health record using structured fields: indication confirmation (ASD/SMS diagnosis code), behavioral intervention completion date, baseline CSHQ score, actigraphy dates, dose initiation/titration dates, and caregiver education topics covered. This ensures continuity across providers and supports value-based care reporting requirements under CMS Quality Payment Program measures.
As pediatric sleep science evolves, so too must our approach to supporting families. Metzli represents not just a new medication—but a commitment to higher standards of evidence, safety, and partnership in caring for children whose sleep needs have long been underserved. Its true measure of success lies not in minutes saved at bedtime, but in the calmer mornings, the more engaged classrooms, and the deeper connections that rest makes possible.
For further guidance, families can access free resources through the Autism Speaks Tool Kit on Sleep Strategies (updated March 2024), the National Institute of Neurological Disorders and Stroke’s SMS Information Page, and the American Academy of Pediatrics’ HealthyChildren.org Sleep Section—all vetted for developmental appropriateness and evidence alignment.
Remember: Every child’s sleep journey is unique. What matters most is meeting your child where they are—with patience, data, and unwavering belief in their capacity to thrive.
